Protagonist Therapeutics, Inc. (PTGX) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Aurinia Pharmaceuticals, Inc.

Tango Therapeutics, Inc.

Deciphera Pharmaceuticals, Inc.

Twist Bioscience Corp.

Iovance Biotherapeutics, Inc.

Geron Corp.

Relay Therapeutics, Inc.

Arvinas, Inc.

Protagonist Therapeutics, Inc.

Disc Medicine, Inc.

Pliant Therapeutics, Inc.

Why is Protagonist Therapeutics, Inc. ?

Poor Management Efficiency with a low ROE of 7.42%

The company has been able to generate a Return on Equity (avg) of 7.42% signifying low profitability per unit of shareholders funds

With a fall in Operating Profit of -663.9%, the company declared Very Negative results in Jun 25

The company has declared negative results in Mar 25 after 5 consecutive negative quarters
NET SALES(Q) At USD 5.55 MM has Fallen at -89.32%
OPERATING PROFIT(Q) Lowest at USD -41.74 MM
PRE-TAX PROFIT(Q) Lowest at USD -34.6 MM

With ROE of 8.16%, it has a expensive valuation with a 4.89 Price to Book Value

Over the past year, while the stock has generated a return of 97.36%, its profits have fallen by -65.3%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Protagonist Therapeutics, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Protagonist Therapeutics, Inc.

111.71%

2.49

68.61%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

65.75%

EBIT Growth (5y)

18.39%

EBIT to Interest (avg)

-33.21

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.83

Sales to Capital Employed (avg)

0.40

Tax Ratio

1.57%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

17.16%

ROE (avg)

7.42%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

4.89

EV to EBIT

102.77

EV to EBITDA

94.50

EV to Capital Employed

24.06

EV to Sales

13.46

PEG Ratio

Dividend Yield

ROCE (Latest)

23.42%

ROE (Latest)

8.16%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

2What is working for the Company

RAW MATERIAL COST(Y)

Fallen by -20.53% (YoY

CASH AND EQV(HY)

Highest at USD 1,144.83 MM

-31What is not working for the Company

NET SALES(Q)

At USD 5.55 MM has Fallen at -89.32%

OPERATING PROFIT(Q)

Lowest at USD -41.74 MM

PRE-TAX PROFIT(Q)

Lowest at USD -34.6 MM

NET PROFIT(Q)

Lowest at USD -34.77 MM

EPS(Q)

Lowest at USD -0.55

Here's what is working for Protagonist Therapeutics, Inc.

Cash and Eqv

Highest at USD 1,144.83 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Raw Material Cost

Fallen by -20.53% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Protagonist Therapeutics, Inc.

Net Sales

At USD 5.55 MM has Fallen at -89.32%

over average net sales of the previous four periods of USD 51.95 MM

MOJO Watch

Near term sales trend is extremely negative

Net Sales (USD MM)

Pre-Tax Profit

At USD -34.6 MM has Fallen at -342.43%

over average net sales of the previous four periods of USD 14.27 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -34.77 MM has Fallen at -347.51%

over average net sales of the previous four periods of USD 14.05 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Operating Profit

Lowest at USD -41.74 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (USD MM)

Pre-Tax Profit

Lowest at USD -34.6 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit

Lowest at USD -34.77 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

EPS

Lowest at USD -0.55

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (USD)